Spain: Strategies for plant protection

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Spain: Strategies for plant protection

The tension in the relationship between patent rights and plant breeder's rights (PBR) is widely known. Recently, some EU member states have opposed the decision taken by the Enlarged Board of Appeals of the European Patent Office (EPO) in cases G2/12 and G2/13 .

G2/12 and G2/13 concluded that plants obtained by an essentially biological process, excluded from patentability according to Article 53(b) EPC, are not excluded from patentability, but in December 2016 the EPO decided to stay all proceedings in examination and opposition cases in which the invention was a plant or animal obtained by an essentially biological process. This decision was taken following the discussion on the recent Notice of the European Commission related to the exclusion from patentability of said plants interpreted from the Biopatent Directive (98/44/EC) and supported by Spain jointly with Austria, Belgium, the Czech Republic, Denmark, France, Germany, Greece, the Netherlands, Norway, Poland, Portugal, Romania and Switzerland.

If finally the EPO follows the interpretation offered by the European Commission Notice, PBRs would be the main route of the protection of plants derived from essentially biological processes.

In order to obtain PBRs, the plant material must be novel, distinct, stable and homogeneous, but also it must be assigned a valid variety denomination. Since time elapsed between the application date and the grant of PBRs, it is advisable to protect this denomination simultaneously as a trade mark but taking into account proceeding of the Guidelines established by the Community and national regulations. At European Community level, at the time the PBR is granted, the trade mark will be annulled since the variety denomination would be generic. Nevertheless, the breeder would have the exclusive right to prevent third parties with an identical or similar denomination during this period. At national level, in Spain, according to the Article 48.4 of the Law No 3/2000, the applicant must undertake to waive the Spanish trade mark rights at the time the PBR is granted.

It is also remarkable that, according to article 19 of the Spanish Regulation (Real Decreto) No 1261/2005 which approves the regulation of protection of plant varieties, it is necessary to register in the corresponding Spanish Ministry a Community plant variety licence contract to ensure that infringements of the corresponding national PBRs are equally applicable to infringements of the Community PBRs. From 2005, the licences of exploitation of PBRs have shown a clear and surprising upward movement, indicating that the PBRs generated by the breeding sector are growing strongly in this country.

Rafa Lopez

Esther Rubio


PONS IPGlorieta Rubén Darío, 428010 – Madrid SpainTel: +34 917007600Fax: +34 913086103clientes@pons.eswww.ponsip.com

more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article